Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena

Catalent, the contract development and manufacturing organization currently being acquired by Novo Holdings, is selling an oral solids manufacturing facility in Somerset, N.J.

Financial details were not disclosed, however the deal is set to close in early 2025, according to a Monday press release. A spokesperson for Catalent told BioSpace by email that the “sale of Somerset is unrelated to the Novo Holdings transaction.”